BRADLEY PHARMACEUTICALS (BPRXA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BRADLEY PHARMACEUTICALS (BPRXA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: harkenman who wrote (32)	10/10/1997 8:05:00 AM
From: F. Jay Abella, III	of 41

Harken: BPRX has successfully resolved its past (with Berlex) and is soldifying its future by bolstering its cash flow and earnings stream. Watch for the Co's earnings in Q3, but Q4 especially, they will be excellent. To be conservative, take the Q4 number and multiply by 4 to get an idea of FY98 EPS, then attach a 15-20 multiple. The stock will go much higher, possibly to the $6-7 range by end of 98. Not a bad return for an emerging pharma company, with little of the downside risks inherent to most companies this size. See my writeup of BPRX at www.westergaard.com under company profiles. FJA

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next